Cronos Australia CEO, Rodney Cocks, said: “We are very pleased to be delivering such a wide range of important new features to our large and growing number of CanView users. The network effect on the platform is clear which will drive further patient, prescriber and pharmacist onboarding. We are confident that the improved functionality of the CanView 2.0 platform will not only provide a superior user experience but help Cronos Australia to maintain its current market-leading position. The CanView 2.0 platform releases are, again, the outcome from an aligned focused Board and Executive with proven execution capabilities. This builds on Cronos Australia being the first profitable ASX-listed medicinal cannabis company and the first to declare a dividend.”
AC8 Price at posting:
4.0¢ Sentiment: Hold Disclosure: Held